Phaseline

Companies › Corcept Therapeutics

Corcept Therapeutics: clinical trials, targets and expected readouts

4 active drug programs in 9 registered trials: 6 Phase 2, 2 Phase 1, 1 Phase 3; Oncology, Neurology, Gastroenterology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
relacorilant
Glucocorticoid receptor antagonist
NR3C1Phase 3Ovarian Neoplasm; Cushing Syndrome; Ovarian Cancer; Adenocarcinoma …Dec 2026
Dazucorilant (CORT113176)
Glucocorticoid receptor antagonist
NR3C1Phase 2Amyotrophic Lateral SclerosisNov 2027
Miricorilant
Glucocorticoid receptor modulator
NR3C1Phase 2Nonalcoholic Steatohepatitis (NASH)–
Nenocorilant
Glucocorticoid receptor antagonist
NR3C1Phase 1NeoplasmsJan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06108219MiricorilantPhase 2Nonalcoholic Steatohepatitis (NASH)GastroenterologyFeb 2026
NCT07553663MiricorilantPhase 1Nonalcoholic Steatohepatitis (NASH)GastroenterologySep 2026
NCT05257408relacorilantPhase 3Ovarian NeoplasmOncologyDec 2026
NCT03604198relacorilantPhase 2Cushing SyndromeOncologyDec 2026
NCT06906341relacorilantPhase 2Ovarian CancerOncologyDec 2026
NCT07276373NenocorilantPhase 1NeoplasmsOncologyJan 2027
NCT07259317relacorilantPhase 2AdenocarcinomaOncologySep 2027
NCT05726292relacorilantPhase 2Prostate CancerOncologyOct 2027
NCT05407324Dazucorilant (CORT113176)Phase 2Amyotrophic Lateral SclerosisNeurologyNov 2027

From the company's SEC filings

Cash and short-term investments of $371m on 2026-09-30; operating cash flow positive

Press releases filed as 8-K in the last year:

Regulatory dates the company has stated

Complete response letters from FDA

Specialist investors

Held by 4 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

NR3C1 (4)

Companies with the same targets

Oticara Australia AstraZeneca Eupraxia Pharmaceuticals Alimera Sciences Laboratorios Sophia S.A de C.V. Optinose US Santhera Pharmaceuticals Pop Test Oncology Pacira Pharmaceuticals Tiohundra

Companies built like this

Jazz Pharmaceuticals Oticara Australia Nurix Therapeutics Exelixis Compass Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.